New study examines Real-World side effects of lung cancer therapies
NCT ID NCT07215962
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study tracks 300 patients with advanced non-small cell lung cancer whose tumors have low PD-L1 levels (below 1%). Researchers will look at side effects and healthcare use for different first-line treatments, including combinations of immunotherapy drugs like nivolumab and ipilimumab with or without chemotherapy. The goal is to understand how these treatments work in everyday practice, outside of controlled clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Florida Cancer Specialists & Research Institute
Fleming Island, Florida, 32003, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nivolumab, ipilimumab, and other immunotherapy drugs combined with chemotherapy
What this could lead to
If successful, this could help doctors choose safer and more effective first-line treatments for advanced lung cancer patients with low PD-L1 levels.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients or settings.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.